

FEE TRANSMITTAL for FY 2003

☐ Applicant claims small entity status. See 37 CFR 1.27.

TOTAL AMOUNT OF PAYMENT (\$): \$80.00

Complete if Known

Application Number: 09-451,641
Filing Date: November 30, 1999
First Named Inventor: D. Gao
Examiner Name: S. Tran
Art Unit: 1615
Attorney Docket No: C-3169-1-US

METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit card ☐ Money Order ☐ Other ☐ None

☒ Deposit Account

Deposit Account Number: 19-1025
Deposit Account Name: Pharmacia Corporation

The Commissioner is authorized to: (check all that apply)

☒ Charge fees indicated below ☐ Credit any overpayments
☒ Charge any additional fees during the pendency of this application
☒ Charge fees indicated below except for the filing fee to the above-identified deposit account.

FEE CALCULATION

1. BASIC FILING FEE

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
1001 750	2001 375	Utility filing fee	
1002 330	2002 165	Design filing fee	
1003 520	2003 260	Plant filing fee	
1004 750	2004 375	Re-issue filing fee	
1005 160	2005 80	Provisional filing fee	
SUBTOTAL (1) (\$)			

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Total Claims	Extra Claims	Fee from below	Fee Paid
Independent Claims	-20** =	X	
Multiple-Dependent Claims	-3** =	X	

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description
1202 18	2202 9	Claims in excess of 20
1201 84	2201 42	Independent claims in excess of 3
1203 280	2203 140	Multiple dependent claims if not paid
1204 84	2204 42	** Reissue independent claims over original patent
1205 18	2205 9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$)

**or number previously paid, if greater. For Reissues, see above.

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
1051 130	2051 65	Surcharge - late filing fee or oath	
1052 50	2052 25	Surcharge - late provisional filing fee or cover sheet	
1053 130	2053 130	Non-English specification	
1812 2,520	2812 2,520	For filing a request for ex parte examination	
1804 920*	2804 920*	Requesting publication of SPR prior to Examiner action	
1805 1,840*	2805 1,840*	Requesting publication of SPR after Examiner action	
1251 110	2251 55	Extension for reply within first month	
1252 410	2252 205	Extension for reply within second month	
1253 930	2253 465	Extension for reply within third month	
1254 1,450	2254 725	Extension for reply within fourth month	
1255 1,970	2255 985	Extension for reply within fifth month	
1401 320	2401 160	Notice of Appeal	
1402 320	2402 160	Filing a brief in support of an appeal	
1403 280	2403 140	Request for oral hearing	
1451 1,510	2451 1,510	Petition to institute a public use proceeding	
1452 110	2452 55	Petition to revive - unavoidable	
1453 1,300	2453 650	Petition to revive - unintentional	
1501 1,300	2501 650	Utility issue fee (or reissue)	
1502 470	2502 235	Design issue fee	
1503 630	2503 315	Plant issue fee	
1460 130	2460 130	Petitions to the Commissioner	
1807 50	2807 50	Processing fee under 37 CFR 1.121(a)	
1806 180	2806 180	Submission of Information Disclosure Sheet	
8021 40	28021 40	Recording each patent assignment per property (times number of properties)	
1809 750	2809 375	Filing a submission after final rejection (37 CFR 1.129(a))	
1810 750	2810 375	For each additional invention to be examined (37 CFR 1.129(b))	
1801 750	2801 375	Request for Continued Examination (RCE)	
1802 900	2802 900	Request for expedited examination of a design application	

Other fee (specify):

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$): 180.00

SUBMITTED BY

Name (Print Name): James C. Forbes

Registration No. (Attorney Agent): 39,457

Telephone: 847-581-6090

Signature:

James C. Forbes

Date:

2/13/03

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is filed and by the USPTO to process an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 15 minutes to complete including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual user. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Gao, D. et al.

ATTORNEY DOCKET NO.: C-31691 US

SERIAL NO.: 09 451,641

GROUP ART UNIT: 1615

FILED: November 30, 1999

EXAMINER:

S. Tran

TITLE: CELECONIB COMPOSITIONS

DATE: February 18, 2003

RECEIVED

FEB 28 2003

TECH CENTER 1600/290

CERTIFICATE OF MAILING

I hereby certify that this communication and its recited enclosures are being deposited with the United States Postal Service as First Class Mail in a package addressed to:
Assistant Commissioner for Patents, Washington, DC 20231 on *February 18, 2003*

Signed

Bernadette Y. Harper
Bernadette Y. Harper

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

This Information Disclosure Statement (IDS) is filed in accordance with the duty of disclosure under 37 C.F.R. § 1.56 and §§ 1.97-1.98, as supplemented by MPEP § 609. Presentation of documents listed on enclosed Form PTO-1449 is not an admission that any listed document is prior art under the Patent Statutes and the right is reserved to antedate any material described in the listed documents by a showing under 37 C.F.R. § 1.131 or otherwise.

This IDS supplements that submitted on March 4, 2000, October 17, 2001, April 26, 2002, and July 10, 2002, and is filed under the provisions of 37 C.F.R. § 1.97(c) accompanied by authorization to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 19-1025.

Respectfully submitted,

James C. Forbes

James C. Forbes
Agent for Applicant
Registration No. 39,457
Tel. (847) 581-6090

Address Correspondence to:
Pharmacia Corporation
Global Patent Department
P.O. Box 1027
St. Louis, MO 63006

Attachments:
Fee Transmittal Sheet
Form PTO-1449
Copies of art cited
Post Card

C-3169/1/US

09/451,641

Applicant

Gao, D. et al.

Filing Date

Group No.

November 30, 1999

1615

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

FEB 7 - 2000

RECEIVED

FEB 28 1999

OTHER DOCUMENTS (Including author, title, date, pertinent pages, etc.)

TECH CENTER 1600 2901

	Desai et al., (1996), Gastrointestinal Uptake of Biodegradable Microparticles: Effect of Particle Size, <i>Pharmaceutical Research</i> , Vol. 13, No. 12, pp. 1838-1845.
	Florence et al., (1995), Factors Affecting the Oral Uptake and Translocation of Polystyrene Nanoparticles: Histological and Analytical Evidence, <i>Journal of Drug Targeting</i> , Vol. 3, pp. 65-70.
	Gershanik et al., (1998), Interaction of a Self-Emulsifying Liquid Drug Delivery System with the Everted Rat Intestinal Mucosa as a Function of Droplet Size and Surface Charge, <i>Pharmaceutical Research</i> , Vol. 15, No. 6, pp. 863-869.
	Kakoulides et al., (1998), Azocrosslinked poly(acrylic acid) for colonic delivery and adhesion specificity in vitro degradation and preliminary ex vivo bioadhesion studies, <i>Journal of Controlled Release</i> , 54, pp. 95-109.
	Kawamori et al., (1998), Chemopreventive Activity of Celecoxib, a Specific Cyclooxygenase-2 Inhibitor, against Colon Carcinogenesis, <i>Cancer Research</i> , 58, pp. 409-412.
	Kulvanich & Stewart, (1987), The effect of particle size and concentrating on the adhesive characteristics of a mode drug carrier interactive system, <i>J. Pharm. Pharmacol.</i> , 39, pp. 673-678.
	McClean et al., (1998), Binding and uptake of biodegradable poly-DL-lactide micro- and nanoparticles in intestinal epithelia, <i>European Journal of Pharmaceutical Sciences</i> , (Website Version) Vol. 6, Issue 2, pp. 153-163.
	Rodriguez et al., (1998), Design of a new multiparticulate system for potential site-specific and controlled drug delivery to the colonic region, <i>Journal of Controlled Release</i> , 55, pp. 67-77.
	Rubinstein, (1995), Approaches and Opportunities in Colon-Specific Drug Delivery, <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 12(2&3), pp. 101-149.
	Smith et al., (1998), Pharmacological analysis of cyclooxygenase-1 in inflammation, <i>Proc. Nat'l. Acad. Sci. USA</i> , Vol. 95, pp. 13313-13318.
	Tirosh & Rubinstein, (1998), Migration of Adhesive and Nonadhesive Particles in the Rat Intestine under Altered Mucus Secretion Conditions, <i>Journal of Pharmaceutical Sciences</i> , Vol. 87, No. 4, pp. 453-456.

Examiner

Date Considered

*Examiner Initial if citation considered, whether or not citation is in conformance with MPEP §609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.